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Primary sclerosing cholangitis (PSC) is a chronic cholangiopathy
characterized by biliary ﬁbrosis, development of cholestasis and
end stage liver disease, high risk of malignancy, and frequent
need for liver transplantation. The poor understanding of its
pathogenesis is also reﬂected in the lack of effective medical
treatment. Well-characterized animal models are utterly needed
to develop novel pathogenetic concepts and study new treatment
strategies. Currently there is no consensus on how to evaluate
and characterize potential PSC models, which makes direct com-
parison of experimental results and effective exchange of study
material between research groups difﬁcult. The International Pri-
mary Sclerosing Cholangitis Study Group (IPSCSG) has therefore
summarized these key issues in a position paper proposing stan-
dard requirements for the study of animal models of PSC.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver
disease of unknown etiology characterized by inﬂammation,14 vol. 60 j 1290–1303
Key Points
• Well-defined animal models for PSC are the basis for 
development of novel pathogenetic concepts and new 
treatment strategies 
• Standardized work-up of animal models for PSC for 
optimized comparison of obtained findings between 
research groups requires definition of housing 
conditions, diet, laboratory testing, tissue harvesting 
and processing, large bile duct and liver imaging, as 
well as biliary physiology
• Histomorphological characterization of the liver should 
include standard staining techniques, such as H&E, 
Sirius red, and PAS staining
• Immunological characterization should include 
characterization of lymphocyte subpopulations by flow 
cytometry and immunohistochemical evaluation of 
adhesion molecules
• Longitudinal studies allow monitoring of progression of 
sclerosing cholangitis, ductular reaction, fibrosis, and 
tumor development
• Detailed histopathological evaluation of the small and 
large intestine should be performed using standardized 
clinical and histopathological scoring systems 
• Large bile duct morphology should be assessed via 
plastination of the bile duct system and/or MRC, the 
latter enabling longitudinal studies 
• Biliary physiology and bile composition should be 
analyzed to explore potential alterations as factors 
determining disease progression and representing 
therapeutic targets
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ﬁbrosis, and strictures of the intra- and extrahepatic bile ducts.
PSC is more prevalent in men and frequently associated with
inﬂammatory bowel disease (IBD), predominantly ulcerative coli-
tis (UC) with a speciﬁc PSC-IBD phenotype [1–5]. As a chronic
progressive disease it may ultimately lead to biliary cirrhosis
and end-stage liver disease [6,7]. Moreover, PSC carries a high
risk for malignancies of the biliary tract and colon, as well as of
the liver and probably the pancreas. These neoplastic complica-
tions have come to represent the principal cause of deaths since
liver transplantation became the standard of care for patients
progressing towards end stage biliary cirrhosis [6–9]. Disease
modifying pharmacologic treatments unfortunately are lacking.
Longitudinal studies in PSC have been restricted by the lack of
early disease markers, low incidence of the disease, and the lim-
ited accessibility of the human biliary tract, all of which may also
represent major reasons for the diminutive progress made in the
understanding of the disease. The pathogenesis of PSC can be
considered as enigmatic [10,11]. A number of different concepts
have recently been reviewed on the potential role of genetic fac-
tors, aberrant lymphocyte homing, leaky gut, vascular defects,
and altered bile composition in PSC [7,10–12]. Moreover, PSC
may still represent a mixed container of yet unrecognized etiolo-
gies and the general perception is that it may fragment into sev-
eral clinical subentities in the near future. Therefore, PSC might
well be designated as a ‘‘syndrome’’ rather than a ‘‘disease
entity’’. Although at ﬁrst glance perhaps semantic, such a re-clas-
siﬁcation (i) may better reﬂect our uncertainties in understand-
ing the pathogenesis, natural history, and response to currently
available treatment of this syndrome and (ii) may provide more
space for future research developments. These developments will
be difﬁcult to come if animal models of PSC will not become
available. The major attributes of an ‘‘ideal PSC model’’ have been
summarized thoughtfully by John Vierling [14] and currently
available animal models for sclerosing cholangitis (SC) have
recently been reviewed in detail elsewhere [15]. In brief, immu-
nogenetically predisposed animals may develop ﬁbrous-oblitera-
tive cholangitis of the intra- and extrahepatic bile ducts at best in
association with inﬂammation of the gut (especially colitis with a
speciﬁc distribution pattern and clinical presentation recently
referred to as PSC-IBD phenotype with predominant right-sided
colitis) and the development of cholangiocellular carcinoma. In
addition, special immunological phenotypes of inﬂammatory
cells inﬁltrating portal tracts (similar to the human situation)
as well as atrophy of cholangiocytes should be present. In an ideal
world such a model would also reﬂect gender aspects such as the
male predominance of PSC (Fig. 1A). As no animal model yet
exists with all these attributes, there is a need for new, well-char-
acterized and highly reproducible PSC animal models to better
understand the pathobiology of PSC and test novel treatment
modalities. Although some of the currently available animal
models show some individual characteristics of PSC, allowing
longitudinal studies and testing of innovative medical treatment
strategies, it is obvious that all of them have substantial limita-
tions in regard to their construct and/or their face validity
(Table 1) [15]. In addition, some of the models may be useful to
study certain pathophysiological aspects of sclerosing cholangitis,
but may not ﬁt well for drug testing (e.g., common bile duct
ligated rodents) [16,17]. It is also clear, that, due to the syndromic
nature of the disease it is very possible that no single ideal model
will ever be generated, and that the study of combinations of spe-
ciﬁc biliary models will turn-out to be the most productive andJournal of Hepatology 2014doable approach. Furthermore, appropriate comparison of differ-
ent experimental ﬁndings is signiﬁcantly limited due to the lack
of guidelines in the characterization using well-deﬁned and gen-
erally accepted standard methods and tests.
In group and individual meetings, the IPSCSG discussed the
need for methodological standards to characterize potential ani-
mal models for PSC. We performed a systematic Medline search
using the combined search terms ‘‘cholangitis’’ and ‘‘animal
model’’ for suitable animal models of SC with biliary ﬁbrosis, with
focus on rodent models since these are currently the most com-
mon. The aim of this position paper is to provide an up-to-date
standardized evaluation and characterization of potential PSC
models to enable better future comparison of data and exchange
of relevant reagents, study specimens, and material including
liver tissue, bile, and serum samples, thus increasing the effec-
tiveness and accelerating the scientiﬁc output of experimental
animal research in the PSC ﬁeld. In keeping with the clinical
(IBD/PSC phenotype), and laboratory characteristics radiological
ﬁndings, and histomorphological hallmarks of PSC [6,18], the
study group proposed a standardized work-up for prospective
mouse models (Table 2). The proposed complete workup how-
ever may not necessarily be performed in studies, which may
well focus on single aspects of PSC.vol. 60 j 1290–1303 1291
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Housing conditions and diet
In the light of recent advancements with rather sophisticated
metabolomics and microbiome analysis, it is essential to formu-
late a standardized diet. Since most biological processes have a
pronounced circadian rhythm, tissue and biological ﬂuids should
preferentially be harvested between 8:00 a.m. and 12:00 noon.
Mice should have free access to water and diet unless speciﬁc
research questions require overnight fasting (which should be
clearly stated). Experiments and tests should be compared in
male and female mice since they may signiﬁcantly differ in
regard to every single aspect discussed below.Standard laboratory testing
Sera should be analyzed for ALT, AP, serum bilirubin, and serum
bile acid (BA) levels, and aliquots kept frozen at 80 C for subse-
quent analyses at the time of sacriﬁce. Longitudinal studies and
estimation of individual changes may be managed via repeated
by retro-orbital blood-sampling, which is however not accom-
plishable in each country due to legal issues and repeated general
anesthesia may also affect liver tests. Upon harvesting, blood
samples can be taken by either cardiac puncture or decapitation.
ALT, AP, and serum bilirubin levels may be determined with stan-
dard clinical measurement techniques. Total murine serum BAs
are commonly measured photometrically using the 3a-hydroxy-
steroid dehydrogenase (HSDH) reaction; however, available
HSDH kits are adjusted for automated multisampler analysis of
primary human, unconjugated, and glycine-conjugated BAs. Thus,
careful standard curve evaluations with unconjugated and tau-
rine-conjugated cholic acid are to be made for manual photomet-
ric measurements of murine BAs. This is of particular importance
for biliary BAs with 1000-fold higher concentration. Interference
with sulfated or glucuronidated BAs is of no concern, since these
conjugates are not formed in signiﬁcant amounts in rodents [20].
For speciﬁc questions, ultra performance liquid chromatography
coupled with electrospray ionization tandem mass spectrometry
is considered state-of-the-art for detailed analysis of the compo-
sition of serum BAs [21–24].Fig. 1. PSC characteristics and attributes of an ideal PSC animal model. (A) Attribu
intrahepatic bile ducts, bile duct replacement by a scar formation (as illustrated by the as
with K19 staining) as shown in human PSC in the upper panel would be mirrored in suc
dilatations of large and medium-sized bile ducts shown with bile duct plastination of a
addition, special immunological phenotypes of inﬂammatory cells inﬁltrating portal trac
present as illustrated by the cartoon (lower panel, left). An association with inﬂammator
the ideal PSC model. Original magniﬁcation for the upper panel 100 and 200. bd, bile
characteristics of early stage (stage I and II) include a diffuse mixed cell inﬂammator
neutrophilic granulocytes (biliary interphase activity) as illustrated by the cartoons (uppe
Further progression of the disease is accompanied by increasing portal ﬁbrosis, ductular
illustrated by the asterisks) with the formation of portal-portal linking septa (biliary
magniﬁcation for the lower panel 100 and 40. bd, bile duct; cv, central vein; dr, duc
Journal of Hepatology 2014Handling of tissue and organs
Body, liver, and spleen weight should be recorded upon harvest-
ing. We suggest a standardized work-up for mouse liver tissue
since there are signiﬁcantmorphological, physiological, and struc-
tural differences between the liver lobes, such as the degree of
ductular reaction, size of bile ducts, degree of steatosis and
hydroxyproline content (Fig. 2). As illustrated in Fig. 2, the liver
lobes are numbered consecutively according to their size from 1
to 7. A central part should be excised from lobes 1 and 2 that is fur-
ther ﬁxed in 4% neutral-buffered formaldehyde solution (parts 1a
and 2a), embedded in parafﬁn and processed for histological
work-up (i.e., H&E, immunhistochemical staining) and a periphe-
ral part excised for cryopreservation.We suggest consistent use of
lobe 3 for hydroxyproline measurement and lobe 5 for RNA isola-
tion. In addition, gallbladder and the extrahepatic bile ducts
should be collected since PSC can affect the entire biliary tree.
A standardized assessment of the small and large intestine
should form an integral part of the work-up for potential PSC
models in the light of the clinical association with PSC-IBD [5].
This should include both small intestinal (in particular ileal) as
well as colonic assessment. Spontaneous signs of intestinal alter-
ations that might not be apparent upon macroscopic examination
need detailed histopathological evaluation including evaluation
of cell proliferation by a blinded specialist histopathologist (see
below, section on IBD). Pancreatic tissue should also be collected
and stored.Standard histomorphological characterization
One major problem in modeling PSC is its longstanding, chroni-
cally progressive, and variable clinical course, which is also mir-
rored in the human situation at least in part in the
histopathological grading system. The histological changes in
human PSC may be divided arbitrarily into four stages (as illus-
trated in Fig. 1B) [25,26]. In stage I, the typical histological
changes are limited to the portal tracts with a diffuse mixed cell
inﬂammatory inﬁltrate around the bile ducts and occasionally
lymphoid follicles or aggregates with some mild ﬁbrosistes of an ideal PSC animal model. Ideally onionskin-type periductal ﬁbrosis of
terisk on SR stained section) and development of bile duct proliferation (visualized
h a model. Typical macroscopic appearance of the biliary tree with strictures and
n Abcb4/ mouse (left) as well as via MRCP in a PSC patient (central panel). In
ts (similar to the human situation) as well as atrophy of cholangiocytes should be
y bowel disease together with male predominance (lower panel) would round off
duct; cv, central vein; pv, portal vein. (B) Histological changes in human PSC. The
y inﬁltrate around the bile ducts, portal edema, ductular reaction and invading
r panel) and by the HE- and SR-stained sections of human PSC livers (lower panel).
reaction (indicated by the arrows), bile duct replacement by a scar formation (as
ﬁbrosis) (stage III) and ﬁnally the development of cirrhosis (stage IV). Original
tular reaction; pv, portal vein.
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Table 1. Animal models of sclerosing cholangitis.
Animal model Species Limitations [Ref.]
Chemically induced cholangitis
TNBS Sprague-Dawley, Lewis rats High mortality rate [101-103]
ANIT Sprague-Dawley rats No large duct involvement
No typical findings on BD
[104,105]
DDC Swiss albino mice
PDX-1 knockout mice plastination
[106,107]
LCA Swiss albino mice No tolerable long-term protocol [108]
Knockout mouse models
Abcb4-/- FVB/N No development of IBD or CCC (but 
HCC)
[86,109]
Cftr-/- C57BL/6J High risk for intestinal obstruction, 
weak spontaneous phenotype 
(without DSS)
[110,111]
fch/fch BALB/c Extrahepatic BD not studied so far [112,113]
Infectious agents
Cryptosporidium parvum BALB/c nu/nu, BALB/c SCID, C57BL/6-
SCID, NIH-III nu/nu
CD40-/-, IFNγ-/-, CD154-/-, CD40-
CD154-/-, Tnfsf5-/-, Tnfrsf1a-/-, Tnfrsf1b-/-, 
Tnfrsf1a/1b-/-, Tnfsf5-Tnfrsf1a-/-, 
Tnfsf5-Tnfrsf1b-/-, Tnfsf5-Tnfrsf1a/1b-/-, 
CD40-Tnfrsf1a/1b-/-
Complex models,
phenotype so far not well 
characterized
[114-116]
Helicobacter hepaticus A/JCr, C3H/HeNCr, C57BL/6NCr, A/J Complex models [118,119]
Experimental biliary obstruction C57BL/6J Technical pitfalls [120]
Models involving enteric bacterial cell-wall components or colitis
SBBO Lewis and Wistar rats
duct involvement
No development of fibrosis; no large
No development of fibrosis; no large
No development of fibrosis; no large
No development of fibrosis; high
No development of fibrosis
[121]
PG-PS Lewis rats
duct involvement
[121]
fMLT Wistar rats
mortality rate
[122,123]
DSS CD-1 mice
duct involvement
[124]
TNBS + ANIT Spraque-Dawley rats [125]
Models of biliary epithelial and endothelial cell injury
Experimental GVHD BALB/c [126]
TNBS Lewis rats Mild phenotype
Low fibrotic response
Low fibrotic response
Lack of colitis, no fibrosis
Low level biliary inflammation, no
fibrosis
[127]
Complete hepatic arterial deprivation Wistar rats [128]
Antigen driven models of biliary injury
Ova-Bil model C57BL/6 mice [129]
Ova-Bil- iFABP-OVA T cell transfer model C57BL/6 mice [130]
ANIT, alpha-naphthylisothiocyanate; CCC, cholangiocellular carcinoma; Cftr, cystic ﬁbrosis transmembrane conductance regulator; DDC, 3,5-diethoxycarbonyl-1,4-dihy-
drocollidine; DSS, dextrane sodium sulfate; fch, ferrochelatase; fMLT, N-formyl L-methionine L-leucin L-tyrosine; GVHD, graft-vs.-host disease; LCA, lithocholic acid; PG-PS,
peptidoglycan-polysaccharide; SBBO, small bowel bacterial overgrowth; TNBS, 2,4,5-trinitrobenzene sulfonic acid.
Review[25,27]. The biliary epithelium shows vacuolated cholangiocytes
or atrophic changes (Fig. 1B) [25]. Stage II shows portal tract
edema with disruption of the parenchymal limiting plate, ductu-
lar reaction and invading neutrophilic granulocytes (biliary inter-
phase activity) [28]. The characteristic bile duct lesion of PSC is a
ﬁbro-obliterative cholangitis with an ‘‘onion skin’’ type of peri-
ductal ﬁbrosis around medium sized and/or larger bile ducts with
degeneration and atrophy of the biliary epithelium. Occasionally,
bile ducts are replaced by ﬁbrotic cords (scars), which may
be found in all stages of PSC [29,30]. Further progression of the
disease is accompanied by increasing portal ﬁbrosis with the
formation of portal-portal linking septa (biliary ﬁbrosis) (stage
III) and ﬁnally the development of cirrhosis (stage IV) [29]. In later1294 Journal of Hepatology 2014stages of the disease the inﬂammation has a tendency to subside,
followed by cholate stasis with feathery degeneration of
periportal hepatocytes and Mallory-Denk body formation [31].
Accordingly, longitudinal histomorphological studies are
required in potential PSC models to follow up the development,
time course, and progression of sclerosing cholangitis, ductular
reaction, ﬁbrosis, and potential tumor development. In new
genetic mouse models, routine histological examination of liver
lobes 1 and 2 using H&E and Sirius red (SR) staining should
be performed at least in 2-, 4- and 8-week as well as 6- and
12-month-old mice. However, this may just be a general policy/
guideline, since different time points for histomorphological
analyses will vary widely, depending on the speciﬁcities of thevol. 60 j 1290–1303
Table 2. Standardized work-up for mouse models.
Biometric (“clinical”) 
data
Serum tests Visualization of the 
bile duct system
Conventional histological 
evaluation liver and 
extrahepatic BDs (eBDs)
Histochemical 
stains (liver and 
eBDs; FFPE)
IHC
(liver and 
eBDs)
IF
(liver and 
eBDs)
EM Bile Histological 
evaluation 
(ileum and 
colon)§
Additional/back-up 
material
Animal activity
and appearance 
(e.g. pilorection)
scoring for 
diarrhoea,
body weight,
food intake
liver weight, spleen 
weight, colon length
ALT, AP,
SBA,
Bilirubin
Plastination of BDs 
with maceration of the 
remaining liver
Cholangiography
MRI, CT
Liver:
Lobular architecture and 
type of fibrosis, portal
inflammation inflammation
inflammation
inflammation
lobular inflammation,
iBDs:
Ductular reaction,
cholestasis
eBDs:
Caliber, epithelial 
membrane integrity,
peribiliary glands 
(proliferation, metaplasia, 
mucin composition)
H&E
Sirius red
PAS
Hall´s stain
Oil red O 
(frozen section)
K19
CD11b
F4/80
CD4
CD8
VCAM-1
LFA-1
ICAM-1
PECAM-1
CX3CL-1
CX3CR-1
α-SMA
ZO-1
Laminin
Cadherin
Tight junction 
alterations, 
features of 
autophagy, 
cellular 
inclusions
composition (BA, 
Bile flow, pH
PL, cholesterol, 
GSH, bicarbonate 
concentrations)
Ileum:
Mucosal 
architecture,
Colon:§,§§
Mucosal 
architecture,
goblet cells
Serum sample 
back-up 
Tissue:
Ileum/colon
spleen, kidney, 
white adipose 
tissue,
brown adipose 
tissue
stool-microbial 
studies
urine
§The use of a histopathological scoring system is recommended [92].
§§The use of a clinical scoring system is recommended [94].
ALT, alanin-aminotransferase; a-SMA, alpha-smooth muscle antigen; AP, alkaline phosphatase; BA, bile acids; CD, cluster of differentiation; CX3CL1, fractalkine; CX3CR-1, CXC3 chemokine receptor; eBDs, extrahepatic
BDs; EM, electron microscopy; FFPE, formalin-ﬁxed parafﬁn-embedded; GSH, glutathione; iBDs, intrahepatic BDs; ICAM-1, intercellular adhesion molecule-1; K19, keratin 19; LFA-1, lymphocyte function-associated
antigen-1; MRI, magnetic resonance imaging; PAS, periodic acid-Schiff; PECAM-1, platelet endothelial cell adhesion molecule-1; PL, phospholipids; SBA, serum bile acids; VCAM-1, vascular cell adhesion molecule-1; ZO-1,
zonula occludens-1.
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Fig. 2. Liver preparation and processing. Liver lobes are numbered consecutively according to their size from 1 to 7. A central part should be excised from lobes 1 and 2
that is further ﬁxed in 4% neutral-buffered formaldehyde solution (parts 1a and 2a), embedded in parafﬁn and processed for histological work-up (i.e., H&E,
immunohistochemical staining) and a peripheral part excised for cryopreservation. Lobe 3 is used for hydroxyproline measurement and lobe 5 for RNA isolation.
Reviewmodel used with signiﬁcantly differing time course, dynamics,
and disease progression.Immunological characterization
PSC patients show a relatively high prevalence of atypical perinu-
clear antineutrophil cytoplasmic antibodies (pANCA) [7,32,33].
However, due to their low speciﬁcity [34], the missing correlation
with PSC activity [35], pANCA are of limited clinical value in PSC
patients [6,15]. In addition, low speciﬁcity was reported for anti-
nuclear (ANA) and anti-smooth muscle antigen (SMA) antibodies,
anti-endothelial cell antibodies, anti-cardiolipin antibodies, thy-
roperoxidase, thyroglobulin and rheumatoid factor in PSC [7]. In
addition, the value of AMA testing in murine models of autoim-
mune biliary diseases mice has recently been questioned due to
its low speciﬁcity [19]. Consequently, serum autoantibody testing
in animal models for PSC is of limited interest.
The inﬂammatory inﬁltrate in PSC suggests that initiation of
the hepatic innate immune response by exogenous triggers such
as pathogen-associated molecular patterns (PAMPs) entering the
portal circulation via a permeable intestinal mucosa might be a
primary inciting event in the pathogenesis of PSC. Accordingly,
inﬂammatory cells, including macrophages, neutrophils, den-
dritic cells (DCs), lymphocytes, and NK cells are activated through
pattern recognition receptors, secrete cytokines and chemokines,
and perpetuate inﬂammatory reaction by activation of NK cells
through IL-12 and recruitment of lymphocytes via TNF-a, IL-1b,
and CXCL8 [36]. In addition, proinﬂammatory cytokines directly
affect the secretory function of cholangiocytes [37–39]. In PSC,
a predominant T cell inﬁltrate can be found in the portal area
[40,41]. The T cell CD4/CD8 ratio shows considerable inconsisten-
cies in different studies in PSC patients [40,41], also reﬂecting the
distribution of T cell subsets within the liver, in which CD4 cells
are seen more commonly in the portal tracts and CD8 cells pre-
dominately in areas of lobular hepatitis [42]. Consequently,
potential PSC models can be characterized using speciﬁc antibod-
ies for CD4 and CD8 lymphocytes, antibodies against neutrophils
and macrophages (e.g., F4/80, CD11b). The liver lymphocyte
population should also be examined and characterized with
ﬂow cytometry. Standardized methods for extracting liver
lymphocytes [43] are recommended. Accordingly, the portal vein1296 Journal of Hepatology 2014is perfused in situ followed by dissection, homogenization of the
liver tissue, and density centrifugation to separate out the
lymphocytes. The lymphocytes should be characterized with
monoclonal antibodies and multi-colour ﬂow cytometry.
Lymphocytes from spleen, thymus and blood should be examined
at the same time to distinguish liver speciﬁc phenomena from
general attributes. The standard examination should include anti-
bodies against CD4, CD8, CD45R/B220, CD25, and CD69, while
more speciﬁc studies should also include other subset markers,
maturation markers, and further activation markers [44]. Since
ﬂow cytometric examination allows quantiﬁcation of different
subsets of lymphocytes and their characteristics but does not give
any information on their microanatomical localization, immuno-
histochemical staining should be added [45]. For immunopheno-
typing, we recommend that at least ﬁve animals to be included in
each group to allow sufﬁcient power to detect statistical differ-
ences. Ideally, the immunophenotyping should be performed
before disease is histologically evident to detect initiating events
and then later at a time point with full-blown histological
phenotype.
Potential animal models for PSC should be studied for their
hepatic and predominately cholangiocellular expression of
ICAM-1, VCAM-1, MadCAM-1, since these markers are upregu-
lated on bile ducts in PSC, which seems to be quite speciﬁc for
PSC [46–56]. This reactive cholangiocyte phenotype plays an
active role in propagating inﬂammation and ﬁbrosis in PSC by
aberrant expression of HLA class molecules and adhesion mole-
cules [44–46]. In line with these data, increased numbers of
LFA1-positive lymphocytes are frequently observed near dam-
aged bile ducts and ICAM-1 expressing cholangiocytes in PSC
[49], suggesting a major pathogenetic role for these mechanisms
[49]. The strong association of PSC and IBD but the frequently
independent clinical course of both prompted Grant and col-
leagues to postulate the ‘‘gut lymphocyte homing hypothesis’’
[52,55]. Several lines of evidence support this elegant hypothesis:
(i) MAdCAM-1 expression, while not detected in normal liver, can
be expressed aberrantly by hepatic endothelium of IBD patients,
especially with concomitant PSC [54,55]. (ii) The intestinal
expression of the vascular adhesion protein-1 (VAP-1) is signiﬁ-
cantly increased in IBD [54] and hepatic expression as well as
serum activity is increased in PSC (iii). The imprinting and
plasticity of gut-homing human T cells requires primary activa-vol. 60 j 1290–1303
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tion or reactivation by gut DCs. The inability of liver DCs to
imprint gut tropism implies that a4b7+ CCR9+ T cells that inﬁl-
trate the liver in PSC are primed in the gut [55]. In addition, over-
expression of CCL25 and its receptor CCR9 is highly speciﬁc for
PSC [55]. It so is reasonable to assume that a MAdCAM-1/a4b7/
CCL25/CCR9 axis plays a crucial role in PSC pathogenesis. Alterna-
tive chemokines that might be involved in PSC pathogenesis
include CCL21 and CCL28, which are implicated in activating
a4b7-integrins and thereby mediate lymphocyte binding to
MAdCAM-1 [51]. The integrin atb6 is overexpressed in biliary
epithelial cells of the ductular reaction and triggers the activation
of TGFb, which is of particular relevance to biliary-type ﬁbrogen-
esis [57,58]. Accordingly, potential animal models for PSC should
be studied for their hepatic expression of ICAM-1, VCAM-1, Mad-
CAM-1, and integrin atb6. Since there is rapid development in
novel research tools for the detection of different chemokines,
cytokines and neuropeptides, investigators should ensure sufﬁ-
cient back-up of liver tissue for cross validation with other mod-
els and human tissue samples.Characterization of ductular reaction and the reactive
cholangiocyte phenotype
This reaction is characterized by atypical thin ductules with elon-
gated structures, lined by ﬂattened cells that are probably the
progeny of the hepatic progenitor/stem cell compartment local-
ized in the canals of Hering. Ductular reaction is frequently
observed in cholestatic liver diseases and may, at least in part,
reﬂect a regenerative response of the liver to cholestatic liver
injury; it also represents a potential trigger for liver ﬁbrosis of
the biliary type, which has to be elucidated in more detail [59–
61].
Typically the ductular reaction is most pronounced at the
periphery of the portal tracts and expands from portal tract to
portal tract [59]. The functional signiﬁcance of this characteristic
histological ﬁnding in cholestatic liver disease is still not entirely
clear and speculation surrounds its potential role in bile forma-
tion, liver regeneration, formation of a kind of bile reservoir,
and as a trigger for liver ﬁbrosis of the biliary type [11]. Studies
should address the dynamics, mechanisms, and impact of this
interesting phenomenon in animal models for PSC. Most impor-
tantly, well characterized animal models should allow detailed
in vivo studies on the important cell-to-cell interactions between
activated proliferating cholangiocytes, inﬂammatory cells, and
portal myoﬁbroblasts with many remaining open questions, since
most of these concepts so far have only been studied using
in vitro systems [62–65].
Ductular proliferation should be quantiﬁed with the aid of
speciﬁc cholangiocellular markers such as the intermediate ﬁla-
ment keratin 19, which is speciﬁcally expressed in normal rodent
cholangiocytes. Since the phenomenon of ductal metaplasia (i.e.,
the de novo expression of keratin 7/19 in cholestatic hepatocytes)
does not seem to represent a prominent feature in cholestatic
rodent models, assessment of ductular reaction by digital image
analysis (morphometry) of K7/19 immunohistochemistry as well
as western blotting for keratin 7 or 19 in the same liver lobes rep-
resent well suited tools for quantiﬁcation of ductular reaction/
proliferation. In addition, morphometric analysis of liver tissue
sections of the same liver lobes may be useful. Furthermore,
progenitor cells destined to be of biliary lineage should beJournal of Hepatology 2014SOX9-, A6-, EpCam-positive [65–70]. However, little is known
so far about the expression pattern of these interesting markers
in different PSC animal models.Characterization and quantiﬁcation of liver ﬁbrosis
PSC patients develop liver ﬁbrosis of the biliary type with pre-
dominant portal ﬁbrosis and porto-portal septa, which may pro-
gress to liver cirrhosis (Fig. 1B). In addition, there is typically
onionskin type periductal ﬁbrosis, particularly around medium-
sized and large bile ducts (Fig. 1A). Comparable to other forms
of liver ﬁbrosis, collagen represents a major extracellular matrix
protein in biliary ﬁbrosis, which is typically found in broadened
portal tracts and porto-portal septa (Fig. 1A). Myoﬁbroblasts
located in portal tracts originate either from hepatic stellate cells
(HSCs) or portal ﬁbroblasts and may represent the main cellular
source of ﬁbrosis in cholestatic liver disease; their proliferation
is mediated by ﬁbroblast growth factor-2 (FGF-2) and inhibited
by TGFb1 and TGFb2 [71–73]. Immunhistochemical studies have
shown that in ﬁbrotic human and rat liver, portal and septal myo-
ﬁbroblasts displayed expression proﬁles that were distinct from
those of interface myoﬁbroblasts or sinusoidally located HSCs,
suggesting that at least two subpopulations of myoﬁbroblasts,
HSC-derived myoﬁbroblasts and portal mesenchymal cell-
derived myoﬁbroblasts, populated the injured liver [74]. To fur-
ther distinguish HSCs from myoﬁbroblasts, speciﬁc stellate cells
markers, including cytoglobin (also known as stellate cell activa-
tion-associated protein – STAP), desmin, cellular retinol-binding
proteins (CRBP) or lecithin-retinol acyltransferase (LRAT), might
be used [75]. However, so far no reliable markers have been iden-
tiﬁed that allowed investigators to fully distinguish HSCs from
portal mesenchymal cells at the stage of myoﬁbroblasts. The rel-
ative contribution of HSCs to biliary ﬁbrosis is in addition receiv-
ing increasing attention. Interestingly, there seems to be an
extensive paracrine interaction between hepatic stellate cells,
portal ﬁbroblasts and activated cholangiocytes involving several
cytokine-, chemokine-, and heat shock protein pathways, which
may be critical for the development and progress of biliary ﬁbro-
sis [76,77]. The relative contribution of HSCs to biliary ﬁbrosis is
in addition receiving increasing attention. However, so far no reli-
able markers have been identiﬁed that allowed investigators to
fully distinguish HSCs from portal mesenchymal cells at the stage
of myoﬁbroblasts.
In animal models for PSC, PAS stain will demonstrate the
thickening of the basal membrane of cholangiocytes and periduc-
tal condensation of ﬁbrosis [78]. SR staining will show periductal
onionskin type ﬁbrosis and porto-portal septa. In general, it is
again critical to compare the same liver lobes (e.g., lobe 3 in
mouse livers) to quantify ﬁbrosis, since in the biliary type there
is enormous variability in ﬁbrosis among the different liver lobes,
also depending on the model studied. Measurement of the pro-
portion of the collagen area seems to represent a useful tool in
human liver tissue samples [79–81] and attempts should be
made to establish this interesting method for use in animal mod-
els as well. Since morphometric analysis of SR-stained liver sec-
tions for quantiﬁcation of liver ﬁbrosis in rodents may present
methodological problems depending on section thickness [82],
direction of cutting, intensity of staining techniques, and
lobular region investigated, it may be best to combine it with
measurement of hydroxyproline content normalized to gram ofvol. 60 j 1290–1303 1297
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Fig. 3. Magnetic resonance imaging of the biliary system of a female Abcb4/ mouse aged 10 weeks. (A) Coronal view of the liver for anatomic reference. Bile is
displayed hyperintense. (B and C) Maximum intensity projections (MIP) of the ventral section of the left liver lobe extracted from a 3D dataset in coronal (B) and transversal
(C) orientation. The intrahepatic bile ducts clearly display a stricture (arrow) and an adjacent duct dilatation. Images were acquired with heavily T2-weighted respiratory-
triggered 3D fast recovery fast spin echo sequence at 7 T ﬁeld strength.
Reviewliver (e.g., from liver lobe 3 in the case of mouse liver, Fig. 2). In
analyses of gene expression reﬂecting ﬁbrogenesis, we suggest
considering collagen 4 and components of the basement mem-
brane such as laminin, heparan sulphate proteoglycan, and ﬁbro-
nectin, which may be preferentially overexpressed in the biliary
type of ﬁbrosis [83]. Moreover, activated myoﬁbroblast markers
such as a-SMA and collagen-a1 may be stained immunohisto-
chemically. Since therapeutic approaches may aim at apoptosis
or silencing of myoﬁbroblasts, speciﬁc staining for activation
(e.g., a-SMA, collagena1, ﬁbronectin, lack of CD34/CD45) or
silencing may be appropriate for speciﬁc research questions [84].Characterization of bile duct tight junction (TJ) alterations
Bile regurgitation is considered to develop at least in late stage
cholangiopathies through leaky bile ducts, bile duct ulceration,
and damaged hepatocytes [85]. A decrease or disappearance of
the TJ protein 7H6 was detected selectively at the hepatocyte
level in PSC patients with immunoﬂuorescence [85]. The lack of
evidence for TJ alterations on the bile duct level in PSC patients
may be related to sampling errors and the inaccessibility of the
bile duct system for systematic studies in a disease primarily
affecting large and medium-sized bile ducts. In order to uncover
the functional signiﬁcance of TJ integrity in PSC, future studies
are needed to determine whether TJ alterations of bile ducts
could play a role. It will be critical to determine whether such
TJ alterations are causative or represent the consequence of bile
duct alterations.
Models for PSC should therefore be explored for potential
tight junction alterations in bile ducts and hepatocytes using
double labeling ﬂuorescence microscopy combining cell speciﬁc
markers (e.g., K8/18 for hepatocytes and K7/19 for cholangio-
cytes) with tight junction protein markers such as E-cadherin
and ZO-1 [86]. In addition, secreted ﬂuorescent biliary com-1298 Journal of Hepatology 2014pounds (e.g., ﬂuorescent bile acids) or alternative tracers might
help to characterize potential hepatocyte and cholangiocellular
tight junction alterations [86]; transelectron microscopy could
also be useful to this end. Transepithelial potential as well as per-
meation of opportunely sized ﬂuorescent dextrans could be
another option for functional characterization of a monolayer of
isolated cholangiocytes [87].Large bile duct imaging – Characterization of strictures and
dilatations
Magnetic resonance cholangiography (MRC) represents a stan-
dard technique for examining PSC patients for strictures and dil-
atations of large and medium-sized bile ducts that eventually
come to resemble a prune tree. Modern ECG-triggered MRI imag-
ing on anesthetized mice using gadoxetate disodium as biliary
contrast medium achieves high resolution MRC, but availability
and experience with this method are currently limited [88]. How-
ever, MRC is an extremely attractive approach to study large duct
morphology in PSC models and has the additional advantage of
allowing repeated imaging for longitudinal studies in individual
animals (Fig. 3). Alternatively, large duct disease and characteris-
tic PSC-like alterations may be assessed using plastination of the
bile duct system followed by chemical maceration of the remain-
ing liver [89]. The term plastination refers to procedures that turn
degradable biological tissues into quite stable specimens by
replacing intra- and/or extracellular tissue ﬂuids with curable
polymers that are inﬁltrated or injected [89]. This technique gives
highly reproducible results and it may also allow future studies to
explore potential alterations of the vascular architecture includ-
ing the peribiliary plexus by parallel plastination of hepatic arter-
ies and portal veins using different colors for bile ducts and
vessels. For reproducible high quality results the following steps
should be followed: the ﬁlling of the investigated system dependsvol. 60 j 1290–1303
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on the viscosity of the injected resin and the pressure applied to
the system. The viscosity of the polymer is reduced by adding
15% acetone, which will shrink the specimens by 15%. For compa-
rable results it is crucial to use the same solution for all speci-
mens. The pressure applied by the system should not exceed
the normal system pressure (i.e., mean intrabiliary pressure
10 mmHg in mice) [90]. It is important to keep the pressure sta-
ble until the polymer is cured. An air cushion chamber should be
used to keep the pressure stable, it should not be reduced or
stopped until the resin has hardened. Finally, maceration in
potassium hydroxide requires gentle treatment of the specimens
to avoid fragmentation of the biliary tree. Each specimen should
be treated in an individual receptacle. To eliminate dissolved tis-
sue, the specimen should be washed gently in lukewarm water,
since hot water will destroy the 3-D appearance by softening
the cured polymer; water and the potassium chloride should be
changed every 24–48 h. The specimen is studied under a
stereomicroscope.Characterization of biliary physiology
As the composition of bile may critically affect the biliary pheno-
type in certain mouse models (e.g., Abcb4/ mice, lithocholic
acid-fed mice, DDC-fed mice) [13,91], biliary physiology and bile
composition should be studied in detail in potential PSC models.
Bile should be sampled under general anesthesia after ligation of
the common bile duct, cannulation of the gall bladder, and at
least ﬁve min’ equilibration time. Animals should be placed on
a heater plate and kept on 38–39.5 C. Bile volume should be
determined gravimetrically to calculate bile ﬂow following nor-
malization to liver weight. Biliary concentration of bile acids, cho-
lesterol, phospholipids, glutathione, and bicarbonate should be
determined to calculate biliary output of each component. Biliary
bile acid concentrations are analyzed with a HSDH assay. Biliary
cholesterol concentrations are measured photometrically at
546 nm after enzymatic hydrolysis and oxidation; the indicator
quinoneimine is formed from hydrogen peroxide and 4-amino-
phenazone in the presence of phenol and peroxidase. Biliary
phospholipid concentrations are analyzed utilizing N-ethyl-N(2-
hydroxy-3-sulofopropyl)-3,5-domethoxyaniline, resulting in a
blue pigment that is measured spectrophotometrically at
600 nm. After protein precipitation in 5% metaphosphoric acid,
biliary glutathione (GSH) concentrations are determined spectro-
photometrically at 356 to 400 nm. To determine biliary bicarbon-
ate, total carbon dioxide, and pH concentration, bile is collected
under mineral oil for 30 min and measured with an automatic
blood gas analyzer. Tissue analyses or serum biochemical testing
of mice used for bile sampling should be avoided due to the long-
term surgical manipulation and resulting artifacts.Characterization of the ‘‘IBD/PSC phenotype’’
There is a well-known coincidence of PSC and inﬂammatory
bowel diseases (IBD) with a special PSC-IBD phenotype [2–5].
Accordingly, we search for immunogenetically predisposed ani-
mals with ﬁbrous-obliterative cholangitis of the intra- and extra-
hepatic bile ducts in association with inﬂammation of the gut
(especially right-sided colitis). Models with sclerosing cholangi-Journal of Hepatology 2014tis, or more generally cholangiopathy models, thus should be
screened for gut inﬂammation and vice versa; potential IBD mod-
els should be tested for the development of sclerosing cholangitis
over time. Consequently, we propose that an experienced pathol-
ogist screens the small and large intestine for inﬂammation using
H&E-stained tissue sections of the ileum, jejunum, caecum, and
left-sided colon in experimental animals. Histopathological fea-
tures are alterations in the crypt-villus ratio (in the small intes-
tine), crypt distortion, assessment of goblet cell numbers and
conﬁguration, neutrophil inﬁltration, and crypt abscess forma-
tion. A histopathological scoring system might be used [92,93].
In the case of clinically apparent colitis, a standardized clinical
scoring system [94], and determination of colon length and
weight should complement this analysis. A critical element of
IBD and experimental models of IBD is the gut microbiome
[95]. This should be assessed on colonic stool samples by next
generation sequencing to detect changes in microbial communi-
ties that drive disease or are altered as a consequence of host
changes e.g., gene deletions or therapies. To correct for microbial
changes related to sourcing and husbandry, animals should –
where possible – be purchased from the same supplier and co-
housed.How should we test therapies in PSC models?
Detailed long-term studies to describe a PSC model are indispen-
sible for meaningful testing of potential therapies and drugs for
PSC. It is essential to determine the times of high disease activity
in relation to inﬂammation and ﬁbrogenesis and those of stable
disease for each particular model to allow ﬁrm conclusions as
whether a tested drug or antibody inhibits or even heals the bil-
iary disease. Best of all, of course, would be prevention vs. rescue
approach. Ideally, a spontaneous genetic model with high con-
struct and face validity without the need of additional surgical
or toxic/infectious manipulations would be available to test
potential drugs.How to test tumor development in PSC models?
To our knowledge there is as yet no murine model with PSC fea-
tures that develops cholangiocellular carcinoma. There are a few
rodent models of hepatocellular cancer (HCC) that arise sponta-
neously within the context of cirrhosis and most of them require
the administration of hepatotoxic and/or carcinogenic agents
[96]. Abcb4/ mice develop nodules and HCC at 6–12 months;
however, this may differ signiﬁcantly depending on the genetic
background [97]. For current and future PSC models, systematic
analysis using MRI techniques combined with careful histological
analysis is recommended. Depending on the frequently varying
life span of the animal models used, livers should be studied sev-
eral times within the last third of the animals’ life (e.g., at 9, 12,
and 15 months). Investigators should also carefully monitor path-
ologically enlarged lymph nodes or extrahepatic spread of tumors
(e.g., lungs), which, however, may be an unusual feature of malig-
nancy in mice in general. Tumor specimens should be investi-
gated by a specialized pathologist using a combination of
routine histological and special immunohistochemical tech-
niques, possibly supported by digital image analysis.vol. 60 j 1290–1303 1299
Review
Could there be already some ‘‘undiscovered’’ PSC mouse
models out there?
There are numerous publications on different mouse models
including genetically modiﬁed inbred mouse strains with a more
or less cholestatic phenotype [13]. Currently, however, we have
no systematic catalogue of all those interesting models including
all the readouts outlined above that should be available in an
open database. As an example, there are no data on bile duct
imaging or bile duct plastination in NOD.c3c4 mice, which also
have large duct disease on liver histology and so could represent
an interesting candidate studies on certain aspects of PSC [13].
Notably, all potential IBD models should be systematically
screened for a PSC-like liver phenotype. Future research activities
should therefore aim for a detailed phenotypic catalogue of
potential PSC models to allow easy and correct selection of a
model for speciﬁc research tools.It is not all about mice: Non-rodent models of PSC
With the advances in genetic engineering with generation of
knockout and transgenic models, mice belong to the most favored
animal species in modern experimental biology and frequently
have to take over the research baton from ﬂies and worms. But
using a very limited number of species to model an obviously
complex disease such as PSC harbors the potential danger that
we limit the possible answers to those that such organisms can
provide [98]. Undoubtedly, mice have numerous advantages
when used as experimental animals including the possibility of
genetic manipulations, well characterized strains, easy handling,
and relatively low costs. Currently, however, there is no ideal
mouse PSC model and there are substantial limitations when
we try to transfer experimental mouse data to the human situa-
tion, mainly due to the obvious disparities between mice and
humans. In addition, there are numerous discouraging examples
of initially promising therapeutic approaches in mouse models in
a diversity of diseases [98,99]. Moreover, mouse models of IBD
must be viewed very cautiously when it comes to advancement
of new therapeutic concepts. We also should bear in mind that
there are very exciting diseases in different species such as scle-
rosing cholangitis with inﬂammatory bowel disease in cats and a
PSC-like phenotype recently described in baboons [100]. This
leads to the question of whether we should increase our range
of experimental animal species and discuss our urgent questions
in regard to human PSC in more detail with specialized veterinar-
ians to speed up and improve our search for a better PSC model.Conclusion
We herein provide a practice guideline for standardized evalua-
tion of potential PSC models that should encourage and facilitate
systematic work-up of different mouse models with a clear chol-
angiopathy phenotype. Importantly, such a systematic approach
is also recommended for novel models with suggestive signs of
a cholestatic phenotype such as increased AP or SBA levels or
ductular reaction. In addition this position paper could represent
the starting point for a common database for potential PSC mod-
els to speed up our PSC research agenda.1300 Journal of Hepatology 2014Conﬂict of interest
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